The therapeutic potential of TREM2 in cancer.
TREM2 (triggering receptor expressed on myeloid cells 2)
immunosuppression
immunotherapy
tumor associated macrophage (TAM)
tumor infiltrating lymphocyte (TIL)
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
01
07
2022
accepted:
03
08
2022
entrez:
19
9
2022
pubmed:
20
9
2022
medline:
20
9
2022
Statut:
epublish
Résumé
Cancer continues to be a substantial health concern and a leading cause of death in the United States and around the world. Therefore, it is important to continue to explore the potential of novel therapeutic targets and combinatorial therapies. Triggering receptor expressed on myeloid cells 2 (TREM2) is a transmembrane receptor of the immunoglobulin superfamily that associates with DNAX activation protein (DAP) 12 and DAP10 to propagate signals within the cell. TREM2 has primarily been recognized for its expression on cells in the monocyte-macrophage lineage, with the majority of work focusing on microglial function in Alzheimer's Disease. However, expansion of TREM2 research into the field of cancer has revealed that epithelial tumor cells as well as intratumoral macrophages and myeloid regulatory cells also express TREM2. In this review, we discuss evidence that TREM2 contributes to tumor suppressing or oncogenic activity when expressed by epithelial tumor cells. In addition, we discuss the immunosuppressive role of TREM2-expressing intratumoral macrophages, and the therapeutic potential of targeting TREM2 in combination with immune checkpoint therapy. Overall, the literature reveals TREM2 could be considered a novel therapeutic target for certain types of cancer.
Identifiants
pubmed: 36119485
doi: 10.3389/fonc.2022.984193
pmc: PMC9479103
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
984193Informations de copyright
Copyright © 2022 Wolf, Fingleton and Hasty.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Genet. 2000 Jul;25(3):357-61
pubmed: 10888890
Oncogenesis. 2019 Jan 25;8(2):9
pubmed: 30683932
Mol Neurodegener. 2017 Aug 2;12(1):56
pubmed: 28768545
Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19531-6
pubmed: 24218563
Oncotarget. 2016 May 17;7(20):29620-34
pubmed: 27102437
J Neurosci. 2015 Feb 25;35(8):3384-96
pubmed: 25716838
Sci Rep. 2016 Dec 09;6:38761
pubmed: 27934908
Trends Mol Med. 2017 Jun;23(6):512-533
pubmed: 28442216
J Exp Med. 2017 Mar 6;214(3):597-607
pubmed: 28209725
Sci Signal. 2010 May 18;3(122):ra38
pubmed: 20484116
Oncotarget. 2016 Jan 19;7(3):2354-66
pubmed: 26506595
J Exp Med. 2005 Feb 21;201(4):647-57
pubmed: 15728241
Neurology. 2005 May 10;64(9):1502-7
pubmed: 15883308
Cell. 2022 Mar 31;185(7):1189-1207.e25
pubmed: 35325594
Cell Mol Life Sci. 2022 Jun 20;79(7):369
pubmed: 35723745
Nat Commun. 2020 Oct 8;11(1):5084
pubmed: 33033253
Immunogenetics. 2012 Jan;64(1):39-47
pubmed: 21800138
J Cell Physiol. 2019 Jun;234(6):8509-8521
pubmed: 30520029
Gut. 2019 Mar;68(3):533-546
pubmed: 29374630
Neurosci Lett. 2017 Nov 1;660:109-114
pubmed: 28923481
J Exp Med. 2015 May 4;212(5):681-97
pubmed: 25897174
Cell. 2017 Aug 10;170(4):649-663.e13
pubmed: 28802038
Front Immunol. 2022 Mar 14;13:848367
pubmed: 35359989
Cancer Res. 2021 Oct 15;81(20):5284-5295
pubmed: 34389631
Mol Neurodegener. 2018 Dec 20;13(1):66
pubmed: 30572908
Am J Hum Genet. 2002 Sep;71(3):656-62
pubmed: 12080485
J Immunol. 2012 Mar 15;188(6):2612-21
pubmed: 22312126
J Exp Med. 2001 Oct 15;194(8):1111-22
pubmed: 11602640
Mol Neurodegener. 2014 Jun 03;9:20
pubmed: 24893973
Cell. 2020 Aug 20;182(4):872-885.e19
pubmed: 32783915
Gut. 2021 Jul;70(7):1345-1361
pubmed: 32907830
Front Immunol. 2021 Feb 17;12:646523
pubmed: 33679809
Mol Neurodegener. 2022 Jun 3;17(1):40
pubmed: 35658903
Hum Pathol. 2018 Feb;72:91-99
pubmed: 29104108
Neurobiol Dis. 2022 Apr;165:105630
pubmed: 35041990
J Mol Biol. 2017 Jun 2;429(11):1607-1629
pubmed: 28432014
J Biol Chem. 2015 Oct 23;290(43):26033-42
pubmed: 26374897
J Immunol. 2003 Jul 15;171(2):594-9
pubmed: 12847223
Cell. 2021 May 27;184(11):2988-3005.e16
pubmed: 34019793
Int J Oncol. 2016 Dec;49(6):2498-2506
pubmed: 27779645
Cancers (Basel). 2019 Sep 06;11(9):
pubmed: 31489935
Cell. 2020 Aug 20;182(4):886-900.e17
pubmed: 32783918
Cell. 2019 Jul 25;178(3):686-698.e14
pubmed: 31257031
Clin Rev Allergy Immunol. 2016 Aug;51(1):48-58
pubmed: 26573914
Cancer Immunol Immunother. 2022 Oct;71(10):2511-2522
pubmed: 35278107